Drug Trial Radar · NCT04108156
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
672
Actual
Start
Sep 30, 2019
Primary completion
Jul 20, 2027
Study completion Jul 20, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.
Conditions
- Diabetic Macular Edema
Interventions
PDS Implant Pre-Filled with 100 mg/mL RanibizumabDrug
Will be administered as per the schedule described in individual arm.
Intravitreal Ranibizumab 0.5 mg InjectionDrug
Will be administered as per the schedule described in individual arm.
Ranibizumab refill exchangeDrug
Will be administered as per the schedule described in individual arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured Using the ETDRS Chart in the Efficacy Population Using a Treatment Policy Strategy for all Intercurrent EventsTime frame: Baseline to Week 64
- Substudy: Number of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs) and Severity of Ocular and Systemic AEsTime frame: Baseline to Week 72
- Substudy: Number of Participants With Adverse Events of Special Interests (AESIs) and Severity of AESIsTime frame: Baseline to Week 72
- Substudy: Duration of AESIsTime frame: Baseline to Week 72
- Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
- Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post-implantation (up to approximately 72 weeks)
- Substudy: Duration of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
- Substudy: Duration of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post-implantation (up to approximately 72 weeks)
- Substudy: Number of Participants With Adverse Device Effects (ADEs) and Severity of ADEsTime frame: Baseline to Week 72
- Substudy: Number of Participants With Anticipated Serious ADEsTime frame: Baseline to Week 72
- Substudy: Duration of Serious ADEsTime frame: Baseline to Week 72
- Substudy: Number of Device DeficienciesTime frame: Baseline to Week 72
Locations
89 sites in 1 country. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Retinal Consultants of Arizona;Opthalmology
Phoenix, Arizona
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Associated Retina Consultants
Phoenix, Arizona
California Retina Consultants
Bakersfield, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California
The Retina Partners
Encino, California
Retina Consultants of Orange County;Clinical Research
Fullerton, California
Jules Stein Eye Institute/ UCLA
Los Angeles, California
Northern California Retina-Vitreous Associates
Mountain View, California
East Bay Retina Consultants
Oakland, California
Doheny Eye Institute
Pasadena, California
California Eye Specialists Medical Group
Pasadena, California
Retina Consultants Medical Group
Sacramento, California
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California
Orange County Retina Medical Group
Santa Ana, California
California Retina Consultants;Research Department
Santa Barbara, California
Eye Center of Northern Colorado
Fort Collins, Colorado
Colorado Clinical Research
Lakewood, Colorado
Retina Group of New England
Waterford, Connecticut
Retina Group of Florida
Fort Lauderdale, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Retina Specialty Institute
Pensacola, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
Southern Vitreoretinal Associates;Research
Tallahassee, Florida
Retina Associates of Florida;Retina Associates of Florida
Tampa, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina
Marietta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Illinois Retina Associates
Joliet, Illinois
University Retina
Lemont, Illinois
Wolfe Eye Clinic
West Des Moines, Iowa
Retina Associates
Lenexa, Kansas
Retina & Vitreous Associates of Kentucky
Lexington, Kentucky
Maine Eye Center
Portland, Maine
The Retina Care Center
Baltimore, Maryland
Johns Hopkins Hospital;Johns Hopkins Med;Wilmer Eye Inst
Baltimore, Maryland
The Retina Group of Washington;Retinal Disease
Chevy Chase, Maryland
Cumberland Valley Retina Consultants;Clinical Research
Hagerstown, Maryland
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.